Karo Pharma AB (publ) reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was SEK 1,965.3 million compared to SEK 1,460.9 million a year ago. Net loss was SEK 140.6 million compared to net income of SEK 31.8 million a year ago. Basic loss per share from continuing operations was SEK 0.56 compared to basic earnings per share from continuing operations of SEK 0.14 a year ago.